Oct 04, 2021 / 12:00PM GMT
Presentation: Zuranolone Data Review
Oct 04, 2021 / 12:00PM GMT
=====================
Corporate Participants
=====================
* Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
* Helen Rubinstein
Sage Therapeutics, Inc. - IR Officer
* Jim Doherty
Sage Therapeutics, Inc. - Chief Research Officer
* Stephen J. Kanes
Sage Therapeutics, Inc. - Chief Medical Officer
=====================
Conference Call Participants
=====================
* Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
* Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
* Joon So Lee
Truist Securities, Inc., Research Division - VP
* Kathryn Smith
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate
* Laura Kathryn Chico
Wedbush Securities Inc., Research Division - SVP of Equity Research
* Madhumita Yennawar
SVB Leerink LLC, Research Division -
Sage Therapeutics Inc
(NAS:SAGE)
$
7.31
-0.19 (-2.53%)
Market Cap: 446.28 Mil
Enterprise Value: -189.95 Mil
PE Ratio: 0
PB Ratio: 0.71
GF Score: 56/100 SAGE Therapeutics Inc Corporate Call - ECNP Encore Presentation: Zuranolone Data Review Transcript
Oct 04, 2021 / 12:00PM GMT
Release Date Price:
$44.35
(-2.08%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot